# Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

> **NCT00427427** · PHASE2 · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 75 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT00427427
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 75 (ESTIMATED)
- **Why stopped:** lack of accrual
- **Last updated:** 2016-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427427, "Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00427427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*